The primary goal of this proposal is to develop opioid peptide aerosol-compatible formulations and an intranasal drug delivery system to deliver mu/delta opioid peptides to the central nervous system (CNS) in effective concentrations as the first step in developing a new class of safe and efficacious pain medications. Administration of traditional mu-opioid analgesics presents numerous problems, including gastrointestinal side effects, drug-drug interactions with other CNS depressants, and physical dependence. Opioid peptides which have dual mu/delta activity are a promising alternative because they possess effective analgesic properties but they tend to have greatly reduced, if any, of these serious side effects. They have been extensively investigated, but their administration has been limited to intracerebroventricular (ICV) or intrathecal (IT) injection, which has effectively prevented their clinical development despite thei considerable therapeutic promise. Opioid peptides administered via ICV or IT injection have also demonstrated an ability to enhance the analgesia of small molecule opioids (SMO), which could be exceptionally clinically useful in patients at risk for opioid toxicity, opiate addiction r who are tolerant of opioids. This approach will rapidly deliver opioid peptides including leu-enkephalin, biphalin, and beta-endorphin for analgesia directly into the CNS while greatly reduced side effect profiles, including tolerance and physical dependence. This approach has the potential to enable this class of opioid drugs which have high analgesic effect and little-to-n associated tolerance, addiction, or safety issues. Impel NeuroPharma has developed a novel aerosol based nasal device (termed a "pressurized olfactory device," or "POD") designed to bypass the blood-brain barrier (BBB) and deliver drugs directly to the brain via the olfactory connections in the upper nasal cavity ("nose-to-brain" delivery). Studies have shown that nose-to- brain delivery can increase CNS concentrations while lowering systemic concentrations with many types of drugs. The principal investigator Dr. John Hoekman and his team have significant experience in developing direct nose-to-brain opioid formulations for POD administration of drugs demonstrating significant improvements in brain:blood ratio as well as rate and extent of analgesia. Impel NeuroPharma Inc. will optimize and develop opioid peptide drug formulations using a non-invasive intranasal aerosol device for direct delivery to the CNS with greatly reduced systemic distribution.

Public Health Relevance

Opioid analgesics represent among the most widely-used and effective pain treatments. Systemic administration of small molecule mu-receptor opioid analgesics presents numerous problems, including gastrointestinal side effects, drug-drug interactions with other CNS depressants, and increased rates of opioid toxicity in special populations such as the elderly and pregnant/lactating women. Opioid peptides are a promising alternative because they possess effective analgesic properties but they tend to have greatly reduced, if any, of these serious side effects. They have been extensively investigated as alternatives to small molecule opioid analgesics, but their administration has been limited to highly invasive injections, which has effectively prevented their clinical development despite their considerable therapeutic promise. Opioid peptides represent a new class of analgesics which have the potential for fewer side effects and lower toxicity, but because they are prevented from entering the central nervous system by the blood-brain barrier, their clinical development has been limited despite their considerable therapeutic promise. Opioid peptides have also demonstrated an ability to enhance the analgesia of traditional small molecule opioids, which could be exceptionally clinically useful in patients at risk for opioid toxicity or opiate addiction. The goal of the proposed study by Impel NeuroPharma, Inc. is to develop a novel analgesic therapy by delivering opioid peptides directly into the brain. Impel NeuroPharma has developed a novel non-invasive drug delivery system called the Pressurized Olfactory Device (POD). The POD is the only nasal device that enables drugs to bypass the blood-brain barrier by delivering drug to the upper part of the nasal cavity where it is absorbed directly into the brain. Using this approach, drugs can be rapidly delivered to the brain which would normally be excluded due to the blood-brain barrier. We envision that this product will enable the development of more effective analgesic products with fewer side effects and lower toxicity. This approach will also enable the delivery of opioid peptides to enhance analgesia of traditional small molecule opioids without increasing opioid dosage, which may provide more effective treatment without increasing incidences of opioid toxicity or addiction.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43DA033096-01
Application #
8253606
Study Section
Special Emphasis Panel (ZRG1-ETTN-C (11))
Program Officer
Singh, Hari
Project Start
2012-02-15
Project End
2012-07-31
Budget Start
2012-02-15
Budget End
2012-07-31
Support Year
1
Fiscal Year
2012
Total Cost
$149,513
Indirect Cost
Name
Impel Neuropharma, Inc.
Department
Type
DUNS #
827915385
City
Normandy Park
State
WA
Country
United States
Zip Code
98166